Abstract: Provided is a compound, including a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein W is a direct bond or an optionally substituted C, and if W is a direct bond, then X1, X2, X3, and X4 are each independently H, OH, or an electrophile, and optionally one pair selected from X1 and X2, X2 and X3, and X3 and X4 forms a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from O, N, and S, and the five-membered ring is optionally substituted with a ?C, an ?S, or an electrophile, and Y1, Y2, Y3, Y4 and Y5 are each independently selected from H, CH3, OH, O—CH3, and NO2, and an electrophile, and optionally Y2 and Y3 form a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from O, N, and S, and the five-membered ring is optionally substituted with a ?C, ?S, or an electrophile.

Abstract: The present invention provides three-dimensional structural information for region II of the erythrocyte binding antigen 175 (EBA-175). Specifically, the present invention provides three-dimensional structural information of erythrocytic receptor binding sites of EBA-175 RII. The three-dimensional structural information is useful in drug design aimed at blocking receptor interaction with EBA-175. Methods for drug design and methods for identifying compounds binding to EBA-175 RII are also provided.

Abstract: This invention provides methods and compositions related to Argonaute proteins and, in certain embodiments, the applications of these methods and compositions to treatment and therapeutics based on RNAi.